Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.

Trial Profile

Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Cancer vaccine (Primary)
  • Indications Head and neck cancer; Lung cancer; Ovarian cancer; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 03 Mar 2017 Planned initiation date changed from 1 Mar 2017 to 1 Jun 2017.
    • 19 Dec 2016 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top